We found that serum ULBP2 levels trended to be higher in patients suffering from NPC (65.5±74.3 pg/mL, p = 0.122, n = 28) compared with healthy controls (51.4±64.6 pg/mL) and were moderately, but significantly, higher in CRC patients (70.6±73.8 pg/mL, p = 0.038, n = 29; Fig. 5A); plasma levels of ULPB2 were not significantly different between healthy individuals (86.1±101.2, n = 25) and GC patients (78.1±79.7 pg/mL, n = 30, p = 0.673; Fig. 5B). Here, ULBP2 is linked to nasopharyngeal carcinoma.